Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients

Therapeutic Drug Monitoring

Volumn 29, Issue 5, 2007, Pages 592-599

  Strom, Tobin ^a   Haschke, Manuel ^a   Zhang, Yan Ling ^a   Bendrick Peart, Jamie ^a,b   Boyd, Jared ^c   Roberts, Mark ^c   Arabshahi, Lili ^c   Marbach, Peter ^d   Christians, Uwe ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b Eurofins Medinet Inc   (Germany)

^c Seradyn   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Certican; Cross reactivity; Drug metabolism; Everolimus; High performance liquid chromatography ultraviolet; Immunoassay; Liquid chromatography tandem mass spectrometry; Metabolite patterns; SDZ RAD

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DRUG METABOLITE; EVEROLIMUS;

ADULT; ARTICLE; BLOOD SAMPLING; CROSS REACTION; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG MONITORING; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ION TRAP MASS SPECTROMETRY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PHARMACODYNAMICS; PRIORITY JOURNAL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MASS SPECTROMETRY; SIROLIMUS; SWITZERLAND;

EID: 34848867270     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181570830     Document Type: Article

References (30)

1. Sedrani R, Cottens S, Kallen J, et al. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc. 1998;30:2192-2194.
2. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation. 1997;64:32-5.
3. Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit. 2002;24:53-8.
4. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs. 2002;11:1845-1857.
5. Kovarik JM. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction. Drugs Today (Barc). 2004;40:101-109.
6. Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs. 2005;14:313-328.
7. Tsuchiya Y, Lansky AJ, Costa RA, et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol. 2006;98:464.
8. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006;12:5165-5173.
9. Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit. 2004;26:499-505.
10. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation. 2002;73:920-925.
11. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83-95.
12. Salm P,Warnholtz C, Boyd J, et al. Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients. Clin Biochem. 2006;39:732-738.
13. Jacobsen W, Serkova N, Hausen B, et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc. 2001;33:514-515.
14. Streit F, Christians U, Schiebel HM, et al. Structural identification of four metabolites of the macrolide immunosuppressant sirolimus after in vitro metabolism by electrospray-MS/MS. Drug Metab Dispos. 1996;24:1272-1278.
15. Serkova N, Hausen B, Berry GJ, et al. Tissue distribution and clinical monitoring of the novel macrolides immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther. 2000;294:323-232.
16. Kirchner GI,Winkler M, Mueller L, et al. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br J Clin Pharmacol. 2000;50:449-454.
17. Kirchner GI, Mueller L, Winkler M, et al. Long-term pharmacokinetics of the metabolites of everolimus and cyclosporine in renal transplant recipients. Transplant Proc. 2002;34:2233-2234.
18. Kirchner GI, Vidal C, Winkler M, et al. LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood. Ther Drug Monit. 1999;21:116-122.
19. Boernsen KO, Egge-Jacobsen W, Inverardi B, et al. Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. J Mass Spectrometr. 2007;42:793-802.
20. Streit F, Christians U, Schiebel HM, et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem. 1996;42:1417-1425.
21. Zhang YL, Bendrick-Peart J, Strom T, et al. Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples. Ther Drug Monit. 2005;27:770-778.
22. Müller C, Schäfer P, Störtzel M, et al. Ion suppression effects in liquid chromatography-electrospray-ionization transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries. J Chromatogr B. 2002;773:47-52.
23. Christians U, Jacobsen W, Serkova N, et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl. 2000;748:41-53.
24. Christians U, Sattler M, Schiebel HM, et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos. 1992;20:186-191.
25. Holt DW, McKeown DA, Lee TD, et al. The relative proportions of sirolimus metabolites in blood using HPLC with mass-spectrometric detection. Transplant Proc. 2004;36:3223-3225.
26. Kuhn B, Jacobsen W, Christians U, et al. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. J Med Chem. 2001;44:2027-2034.
27. Christians U, Strom T, Zhang YL, et al. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2006;28:39-44.
28. Christians U, Schmitz V, Haschke M. Functional interactions between p-glycoprotein and CYP3A in drug metabolism. Exp Opin Drug Metab Toxicol. 2005;4:641-654.
29. Boyd J, Arabshahi L, Roberts M, et al. A new FPIA immunoassay for the quantitative determination of everolimus in whole blood. Ther Drug Monit. 2005;27:213-214.
30. Strom T, Haschke M, Boyd J, et al. Cross-reactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus. Ther Drug Monit. 2007. In press.